HRP20170608T1 - Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina - Google Patents
Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina Download PDFInfo
- Publication number
- HRP20170608T1 HRP20170608T1 HRP20170608TT HRP20170608T HRP20170608T1 HR P20170608 T1 HRP20170608 T1 HR P20170608T1 HR P20170608T T HRP20170608T T HR P20170608TT HR P20170608 T HRP20170608 T HR P20170608T HR P20170608 T1 HRP20170608 T1 HR P20170608T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenylsulfanyl
- piperazine
- dimethyl
- phenyl
- drug
- Prior art date
Links
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title claims 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (4)
1. 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazin i njegove farmaceutski prikladne soli za uporabu u liječenju depresije ili anksioznosti u bolesnika koji je prethodno primao lijek za liječenje te bolesti, a koji je lijek prekinut zbog nuspojava vezanih uz težinu.
2. 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazin i njegove farmaceutski prikladne soli prema zahtjevu 1 koji je bromovodična sol.
3. Uporaba 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina i njegovih farmaceutski prikladnih soli u proizvodnji lijeka za liječenje depresije ili anksioznosti u bolesnika koji je prethodno primao lijek za liječenje te bolesti, a koji je lijek prekinut zbog nuspojava vezanih uz težinu.
4. Uporaba prema zahtjevu 3, gdje je ta farmaceutski prikladna sol bromovodična sol.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37588510P | 2010-08-23 | 2010-08-23 | |
| DKPA201000739 | 2010-08-23 | ||
| PCT/DK2011/050317 WO2012025123A1 (en) | 2010-08-23 | 2011-08-22 | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| EP11749331.2A EP2608789B1 (en) | 2010-08-23 | 2011-08-22 | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170608T1 true HRP20170608T1 (hr) | 2017-07-28 |
Family
ID=44532506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170608TT HRP20170608T1 (hr) | 2010-08-23 | 2017-04-18 | Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20130184291A1 (hr) |
| EP (1) | EP2608789B1 (hr) |
| JP (1) | JP5902169B2 (hr) |
| KR (1) | KR101816953B1 (hr) |
| CN (1) | CN103068389A (hr) |
| AP (1) | AP3583A (hr) |
| AR (1) | AR082501A1 (hr) |
| AU (1) | AU2011295465B8 (hr) |
| BR (2) | BR122020025600A2 (hr) |
| CA (1) | CA2807062C (hr) |
| CL (1) | CL2013000492A1 (hr) |
| CO (1) | CO6680652A2 (hr) |
| CY (1) | CY1118886T1 (hr) |
| DK (1) | DK2608789T3 (hr) |
| ES (1) | ES2625142T3 (hr) |
| HR (1) | HRP20170608T1 (hr) |
| HU (1) | HUE034155T2 (hr) |
| IL (1) | IL224371A (hr) |
| LT (1) | LT2608789T (hr) |
| ME (1) | ME02674B (hr) |
| MX (1) | MX349724B (hr) |
| PL (1) | PL2608789T3 (hr) |
| PT (1) | PT2608789T (hr) |
| RS (1) | RS55851B1 (hr) |
| RU (1) | RU2564666C2 (hr) |
| SG (1) | SG187649A1 (hr) |
| SI (1) | SI2608789T1 (hr) |
| TW (1) | TW201212918A (hr) |
| WO (1) | WO2012025123A1 (hr) |
| ZA (1) | ZA201301385B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| CN109310691A (zh) | 2016-07-01 | 2019-02-05 | H.隆德贝克有限公司 | 用于快速开始抗抑郁作用的给药方案 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| DE69210959T2 (de) * | 1991-11-18 | 1996-09-26 | Lilly Industries Ltd | Benzo(b)thiophen-2-carboxamide zur Behandlung von Krankheiten des Zentralnervensystems |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| AU2002211367A1 (en) | 2000-10-02 | 2002-04-15 | Rohr, Inc. | Apparatus, method and system for gas turbine engine noise reduction |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| ES2379200T5 (es) | 2006-06-16 | 2021-10-20 | H Lundbeck As | Bromhidrato de 1-[2-(2,4-Dimetilfenilsulfanil)fenil]piperazina como compuesto con recaptación de serotonina combinada con actividad 5-HT3 y 5-HT1A para el tratamiento del deterioro cognitivo |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
-
2011
- 2011-08-17 TW TW100129338A patent/TW201212918A/zh unknown
- 2011-08-19 AR ARP110103029A patent/AR082501A1/es not_active Application Discontinuation
- 2011-08-22 PL PL11749331T patent/PL2608789T3/pl unknown
- 2011-08-22 AU AU2011295465A patent/AU2011295465B8/en active Active
- 2011-08-22 PT PT117493312T patent/PT2608789T/pt unknown
- 2011-08-22 RU RU2013112890/15A patent/RU2564666C2/ru active
- 2011-08-22 BR BR122020025600A patent/BR122020025600A2/pt not_active Application Discontinuation
- 2011-08-22 AP AP2013006768A patent/AP3583A/xx active
- 2011-08-22 RS RS20170404A patent/RS55851B1/sr unknown
- 2011-08-22 SI SI201131177A patent/SI2608789T1/sl unknown
- 2011-08-22 CN CN2011800406861A patent/CN103068389A/zh active Pending
- 2011-08-22 SG SG2013007380A patent/SG187649A1/en unknown
- 2011-08-22 ME MEP-2017-94A patent/ME02674B/me unknown
- 2011-08-22 KR KR1020137004481A patent/KR101816953B1/ko active IP Right Grant
- 2011-08-22 DK DK11749331.2T patent/DK2608789T3/en active
- 2011-08-22 JP JP2013525143A patent/JP5902169B2/ja active Active
- 2011-08-22 LT LTEP11749331.2T patent/LT2608789T/lt unknown
- 2011-08-22 EP EP11749331.2A patent/EP2608789B1/en active Active
- 2011-08-22 HU HUE11749331A patent/HUE034155T2/en unknown
- 2011-08-22 MX MX2013001570A patent/MX349724B/es active IP Right Grant
- 2011-08-22 BR BR112013002194A patent/BR112013002194A2/pt not_active Application Discontinuation
- 2011-08-22 US US13/812,073 patent/US20130184291A1/en not_active Abandoned
- 2011-08-22 ES ES11749331.2T patent/ES2625142T3/es active Active
- 2011-08-22 CA CA2807062A patent/CA2807062C/en active Active
- 2011-08-22 WO PCT/DK2011/050317 patent/WO2012025123A1/en active Application Filing
-
2013
- 2013-01-23 IL IL224371A patent/IL224371A/en active IP Right Grant
- 2013-02-20 CL CL2013000492A patent/CL2013000492A1/es unknown
- 2013-02-21 CO CO13035030A patent/CO6680652A2/es unknown
- 2013-02-22 ZA ZA2013/01385A patent/ZA201301385B/en unknown
-
2017
- 2017-04-18 HR HRP20170608TT patent/HRP20170608T1/hr unknown
- 2017-05-10 CY CY20171100501T patent/CY1118886T1/el unknown
-
2018
- 2018-09-07 US US16/124,497 patent/US20190000836A1/en not_active Abandoned
-
2020
- 2020-05-18 US US16/877,108 patent/US20210085674A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/570,998 patent/US20220370439A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170608T1 (hr) | Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina | |
| HRP20200665T1 (hr) | Bifenilsulfonamidni antagonist receptora za endotelin i angiotenzin ii za liječenje glomeruloskleroze i iga-inducirane nefropatije | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| HRP20120144T4 (hr) | Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost | |
| ME02414B (me) | Tretman kronove bolesti lakvinimodom | |
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| HRP20200662T1 (hr) | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak | |
| JP2012136529A5 (hr) | ||
| HRP20180602T1 (hr) | Farmaceutska kombinacija | |
| HK1200337A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| NZ708959A (en) | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| IL220698A (en) | Annotation (s) –n– (4– (4– acetylpiperazine – 1 – ram) benzyl) - n– (1– (4 – benzylpiperazine – 1 – ram) –1 – oxo-3-phenyl-propane-2-ram ) Acrylamide, containing and using pharmaceutical preparations for the preparation of medicines | |
| JP2015509917A5 (hr) | ||
| SI2729474T1 (en) | (TIENO (2,3-b) (1,5) BENZOXAZEPIN-4-YL) PIPERAZINE-1-IL COMPOUNDS AS TWO ACTIVE H1 INVERTIVE AGENTS / 5-HT2A ANTAGONISTS | |
| MX366353B (es) | Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico. | |
| JP2016540799A5 (hr) | ||
| HRP20211309T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti | |
| IL238071B (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| EP2842938A4 (en) | NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT |